Q1 2027 Metropolis Healthcare Ltd Earnings Call Transcript
Key Points
- Revenue grew 17% YoY to INR450 crores, exceeding the company's stated guidance, driven primarily by volume growth.
- EBITDA margin expanded by 210 basis points to 25.2%, ahead of guidance, due to operating leverage and efficiency gains.
- Specialty diagnostics portfolio grew 17% YoY, with genomics portfolio doubling and contributing to faster growth in high-value testing.
- North India revenue grew 19% YoY, now contributing 18% of total revenue, driven by successful integration of Core Diagnostics and other acquisitions.
- Network expansion is on track with 300 centers added in Q1 FY27, targeting 400-500 net additions for the year, improving accessibility in Tier 2 and Tier 3 markets.
- TruHealth portfolio grew 22% YoY, with premium packages and radiology-integrated wellness offerings growing over 40-50%.
- Core Diagnostics integration is progressing well, with the acquisition multiple effectively at ~10x EBITDA in FY27, demonstrating value creation.
- B2C segment grew 18% YoY, with rural centers delivering 36% revenue growth, indicating strong demand in underserved markets.
- The company maintains a strong quality focus with 99% ECA score and 99.99% report accuracy, reinforcing clinician trust.
- International business continues to perform well, with market leadership in 2 of 5 African markets and healthy revenue and EBITDA growth.
- No price increases have been implemented for 18 months, limiting revenue growth from pricing and relying solely on volume and mix.
- CGHS price revision benefit is minimal for Metropolis, as it contributes only ~1% of total revenue, unlike peers.
- The company rationalized 300 centers in Q1 FY27, indicating some underperformance in certain locations, though it claims no revenue impact.
- Core Diagnostics still has high single-digit EBITDA margins, which are lower than the company average, and will take 3-4 years to reach 25%.
- Management refrained from raising guidance despite Q1 outperformance, citing unpredictability in weather and seasonality, which may signal caution.
- The company is not planning price hikes in the near term, which could pressure margins if inflation rises.
- Network expansion into Tier 2 and Tier 3 towns may initially strain margins, though management expects operating leverage to offset this.
- The diagnostics industry faces intense competition, with new entrants focusing on volume at high servicing costs, potentially disrupting pricing dynamics.
- The company's growth is heavily dependent on weather and seasonal factors, which are increasingly unpredictable due to climate change.
- The integration of recent acquisitions, while progressing, still requires significant management attention and may pose execution risks.
Ladies and gentlemen, good day, and welcome to the Q1 FY27 earnings conference call of Metropolis Healthcare Limited, hosted by JM Financial Institutional Securities.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on the date of this call. These statements do not guarantee the future performance of the company and may involve risks and uncertainties, which are difficult to predict. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Abin Benny from JM Financial Institutional Securities. Thank you, and over to you, sir.
Thank you, Albert. Good morning, and warm welcome to all participants on the Metropolis Healthcare 1Q FY27 earnings call hosted by JM Financial. Today on this call, we have with us the management, Ms. Ameera Shah, Promoter and Chairperson; Mr. Surendran Chemmenkotil, Managing Director; Mr. Sameer Patel
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
